Local view for "http://purl.org/linkedpolitics/eu/plenary/2011-02-16-Speech-3-200-000"
| Predicate | Value (sorted: default) |
|---|---|
| rdf:type | |
| dcterms:Date | |
| dcterms:Is Part Of | |
| dcterms:Language | |
| lpv:document identification number |
"en.20110216.11.3-200-000"2
|
| lpv:hasSubsequent | |
| lpv:speaker | |
| lpv:spokenAs | |
| lpv:translated text |
"The counterfeiting of medicines has become a profitable business, with minimal risk of accountability before the law. This situation is highlighted by the fact that, in 2008 alone, the customs authorities announced that more than 34 million counterfeit medicinal products were confiscated in Europe. Admittedly, the EU has not yet reached the situation of other geographical areas where up to 30% of the medicines available on the market are counterfeit. However, the EU must not allow this situation to be reached. It is currently estimated that 1% of medicinal products sold are counterfeit, but there are warnings indicating that this proportion is on the rise. The new safety regulations adopted by Parliament, the penalties imposed on the manufacturers of counterfeit medicines and the control system between manufacturers and consumers are intended to halt the growth of the pharmaceutical black market in the EU.
Therefore, the introduction of new, mandatory safety regulations governing the trading of medicinal products, including those sold via the Internet, is a welcome step. Selling counterfeit medicines is a criminal activity with serious repercussions which can affect a huge number of consumers who very often choose the easy route of the Internet to order medicines which they would otherwise not be able to access without a medical recommendation."@en1
|
Named graphs describing this resource:
The resource appears as object in 2 triples